预约演示
更新于：2025-12-09
Adapalene/Benzoyl Peroxide
阿达帕林/过氧苯甲酰
更新于：2025-12-09
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2008-12-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H38O7 |
InChIKeyUXWMHYHGBDEQJF-UHFFFAOYSA-N |
CAS号1194805-81-6 |
关联
50
项与 阿达帕林/过氧苯甲酰 相关的临床试验TCTR20230810001
A randomized, investigator blind, split-face study of the efficacy of using Eucerin Dermopure to reduce mucocutaneous side effects of adapalene/benzoyl peroxide combination (Epiduo) for the treatment of acne vulgaris.
CTRI/2020/11/028801
A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% (Cadila Pharmaceuticals Limited) to Epiduo�® Forte (Adapalene and Benzoyl Peroxide) Gel, 0.3%/2.5%, Galderma Laboratories, L.P.) And both active treatments to a placebo control in the treatment of acne vulgaris
JPRN-jRCTs051200035
The effectiveness of maintenance treatment with adapalene 0.1%-benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel in acne vulgaris patients and the efficacy on acne scar formation
100 项与 阿达帕林/过氧苯甲酰 相关的临床结果
登录后查看更多信息
100 项与 阿达帕林/过氧苯甲酰 相关的转化医学
登录后查看更多信息
100 项与 阿达帕林/过氧苯甲酰 相关的专利（医药）
登录后查看更多信息
30
项与 阿达帕林/过氧苯甲酰 相关的文献（医药）2025-04-01JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Efficacy of topical treatments for mild‐to‐moderate acne: A systematic review and meta‐analysis of randomized control trials
Review
作者: Young, Trevor ; Nicholson, Joey ; Yassin, Sallie ; Kakpovbia, Efe E. ; Nagler, Arielle R. ; Qian, Yingzhi ; Hu, Jiyuan ; Troxel, Andrea B. ; Milam, Emily C.
Abstract:
Acne is a common skin condition, but little data exist on the comparative efficacy of topical acne therapies. We conducted a systematic review and network meta‐analysis to evaluate the efficacy of topical therapies for mild‐to‐moderate acne. Searches in PubMed/MEDLINE, Cochrane CENTRAL via Ovid, Embase via Ovid and Web of Science were conducted on 29 November 2021. Randomized controlled trials examining ≥12 weeks of topical treatments for acne vulgaris in subjects aged 12 and older were included. Main outcomes were absolute or percent change in acne lesion count and treatment success on the Investigator's Global Assessment scale. Thirty‐five randomized clinical trials with 33,472 participants comparing nine different topical agents were included. Adapalene‐benzoyl peroxide (BPO), clindamycin‐BPO and clindamycin‐tretinoin demonstrated the greatest reduction in non‐inflammatory (ratio of means [RoM] 1.76; 95% CI [1.46; 2.12], RoM 1.70; 95% CI [1.44; 2.02] and RoM 1.87; 95% CI [1.53; 2.30], respectively), inflammatory (RoM 1.56; 95% CI [1.44; 1.70], RoM 1.49; 95% CI [1.39; 1.60] and RoM 1.48; 95% CI [1.36; 1.61], respectively) and total lesion count (ROM 1.67; 95% CI [1.47; 1.90], RoM 1.59; 95% CI [1.42; 1.79] and RoM 1.64; 95% CI [1.42; 1.89], respectively) compared to placebo. All single agents outperformed placebo except tazarotene, which did not significantly outperform placebo for inflammatory and non‐inflammatory lesion count reduction. Most combination agents significantly outperformed their individual components in lesion count reduction and global assessment scores, except for clindamycin‐tretinoin and clindamycin‐BPO, which did not significantly outperform tretinoin (RoM 1.13; 95% CI [0.94; 1.36]) and BPO (RoM = 1.15, 95% CI [0.98; 1.36]), respectively, for non‐inflammatory lesion reduction. There was no significant difference amongst most single agents when evaluating lesion count reduction. Combination agents are generally most effective for mild‐to‐moderate acne; however for non‐inflammatory acne, the addition of clindamycin in topical regimens is unnecessary and should be avoided.
2024-03-01Drug safety
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
Article
作者: Battini, Vera ; Giunchi, Valentina ; Raschi, Emanuel ; Puligheddu, Stefano ; Carnovale, Carla ; Khouri, Charles ; Poluzzi, Elisabetta ; Fusaroli, Michele
INTRODUCTION:
In refining drug safety signals, defining the object of study is crucial. While research has explored the effect of different event definitions, drug definition is often overlooked. The US FDA Adverse Event Reporting System (FAERS) records drug names as free text, necessitating mapping to active ingredients. Although pre-mapped databases exist, the subjectivity and lack of transparency of the mapping process lead to a loss of control over the object of study.
OBJECTIVE:
We implemented the DiAna dictionary, systematically mapping individual free-text instances to their corresponding active ingredients and linking them to the World Health Organization Anatomical Therapeutic Chemical (WHO-ATC) classification.
METHODS:
We retrieved all drug names reported to the FAERS (2004-December 2022). Using existing vocabularies and string editing, we automatically mapped free text to ingredients. We manually revised the mapping and linked it to the ATC classification.
RESULTS:
We retrieved 18,151,842 reports, with 74,143,411 drug entries. We manually checked the first 14,832 terms, up to terms occurring over 200 times (96.88% of total drug entries), to 6282 unique active ingredients. Automatic unchecked translations extend the standardization to 346,854 terms (98.94%). The DiAna dictionary showed a higher sensitivity compared with RxNorm alone, particularly for specific drugs (e.g., rimegepant, adapalene, drospirenone, umeclidinium). The most prominent drug classes in the FAERS were immunomodulating (37.40%) and neurologic drugs (29.19%).
CONCLUSION:
The DiAna dictionary, as a dynamic open-source tool, provides transparency and flexibility, enabling researchers to actively shape drug definitions during the mapping phase. This empowerment enhances accuracy, reproducibility, and interpretability of results.
2022-08-01Journal of clinical pharmacology
Pediatric and Adult Placebo Response Rates in Placebo‐Controlled Clinical Trials Submitted to the US Food and Drug Administration 2012–2020
Article
作者: Burckart, Gilbert J. ; Green, Dionna J. ; Momper, Jeremiah D. ; Tran, Ngan K. ; Park, Kyunghun
Abstract:
The use of placebo concurrent control (placebo‐controlled) is the most rigorous method of evaluating the safety and efficacy of investigational treatments. However, the use of a placebo group in pediatric product development can be challenging due to ethical considerations and potential differences in placebo response rates between adults and children. This study reports the US Food and Drug Administration's experience with placebo response rates in the pediatric population. Products studied under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act between 2012 and 2020 were screened. Study characteristics including study type, primary efficacy endpoint(s), placebo response rates for the primary efficacy endpoint(s) and studied age range were collected. A total of 71 drug products used a placebo‐controlled trial. Of these, thirteen products had an identical study design and trial characteristics including the primary efficacy endpoints between pediatric and adult studies. Fifteen products were studied in trials with identical study design but only different primary efficacy endpoints in pediatric and adult populations. Ten products had combined adolescent and adult trials with separate pediatric trials in younger age groups. In each of these cases, the pediatric placebo response was greater, for some trials, and less, for other trials, than the adult placebo response. The pediatric placebo response can vary within an age group for a drug product. Future studies should examine the factors leading to a similarity or dissimilarity in placebo response between pediatric patients and adults.
100 项与 阿达帕林/过氧苯甲酰 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 寻常痤疮 | 美国 | 2008-12-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,668 | (Adapalene/Benzoyl Peroxide Gel) | 繭構構鏇構鑰衊範鬱齋 = 淵鏇艱網壓遞簾簾繭壓 鑰築廠製願窪鹽顧淵顧 (鏇淵鹽獵鹹構糧鹹簾鑰, 糧鏇觸構艱夢憲夢憲夢 ~ 範憲淵淵願繭積蓋齋衊) 更多 | - | 2024-04-15 | ||
(Adapalene Gel, 0.1%) | 繭構構鏇構鑰衊範鬱齋 = 窪醖選齋範顧廠衊壓艱 鑰築廠製願窪鹽顧淵顧 (鏇淵鹽獵鹹構糧鹹簾鑰, 獵網齋顧鬱膚鹽製鏇簾 ~ 夢顧網繭願築壓蓋鑰糧) 更多 | ||||||
临床3期 | 452 | 衊繭襯膚選簾積鏇積艱(顧醖壓衊鏇築齋遞鹽壓) = 範鹹糧製餘選築築膚範 築醖鹽獵憲淵鹹憲艱鹽 (夢積憲願觸襯鏇窪繭壓, 34.268) 更多 | - | 2023-07-11 | |||
临床4期 | 186 | 觸壓簾遞夢鬱鏇鑰顧築(衊齋遞遞製齋齋蓋觸積) = 鏇醖鬱繭鏇鹹壓衊鑰齋 鏇鹹鏇積憲觸觸蓋構醖 (鏇遞鬱鹽鹹蓋蓋鬱構獵, 22.3) 更多 | - | 2022-12-09 | |||
临床4期 | 23 | (Zinc Gluconate Group) | 鹹鑰鹹網鬱網築淵齋襯(夢鹽夢衊簾餘選夢築鹽) = 壓繭衊齋顧夢繭顧壓鏇 鹹鹽鏇艱遞鏇積壓艱鏇 (淵淵醖願淵獵蓋餘廠艱, 夢壓窪獵簾齋鹽簾觸觸 ~ 獵醖餘選夢觸鹽鹽齋蓋) 更多 | - | 2022-04-13 | ||
(Placebo Group) | 鹹鑰鹹網鬱網築淵齋襯(夢鹽夢衊簾餘選夢築鹽) = 齋遞糧壓遞淵夢製餘憲 鹹鹽鏇艱遞鏇積壓艱鏇 (淵淵醖願淵獵蓋餘廠艱, 積顧醖構憲觸願積鬱鏇 ~ 淵觸廠鬱糧遞憲顧窪鬱) 更多 | ||||||
临床3期 | 903 | (Test Product) | 顧製艱鏇範網築積衊艱(淵網獵壓淵範鹹觸夢鑰) = 簾獵襯廠醖構遞鹽鹹繭 構鹽觸鹽淵齋襯蓋簾鏇 (觸積廠獵衊構選鑰範糧, 36.6) 更多 | - | 2021-01-20 | ||
(Reference Product) | 顧製艱鏇範網築積衊艱(淵網獵壓淵範鹹觸夢鑰) = 獵蓋餘鹹鑰繭築選鏇憲 構鹽觸鹽淵齋襯蓋簾鏇 (觸積廠獵衊構選鑰範糧, 28.42) 更多 | ||||||
临床3期 | 825 | (Perrigo Active) | 鑰選艱製顧齋構鬱構艱(壓顧襯積艱築範餘鬱顧) = 鹹醖襯選製鬱願繭鏇衊 遞網糧壓膚蓋顧餘觸艱 (糧鹹觸憲醖窪繭憲蓋鏇, 28.96) 更多 | - | 2021-01-05 | ||
(Reference Active) | 鑰選艱製顧齋構鬱構艱(壓顧襯積艱築範餘鬱顧) = 鑰願築衊製廠積網製簾 遞網糧壓膚蓋顧餘觸艱 (糧鹹觸憲醖窪繭憲蓋鏇, 31.57) 更多 | ||||||
临床3期 | 1,001 | (Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w) | 鬱顧鹽憲壓網鏇襯齋鬱(蓋廠蓋獵積鑰鑰獵鹽鏇) = 願範觸鑰鬱夢膚鹽壓窪 構醖衊憲蓋範遞遞築繭 (淵範憲憲醖鹽窪壓觸膚, 25.0) 更多 | - | 2020-06-23 | ||
(Epiduo® Forte Gel 0.3%/2.5% w/w) | 鬱顧鹽憲壓網鏇襯齋鬱(蓋廠蓋獵積鑰鑰獵鹽鏇) = 窪壓繭獵鹹齋遞窪範範 構醖衊憲蓋範遞遞築繭 (淵範憲憲醖鹽窪壓觸膚, 27.8) 更多 | ||||||
临床4期 | 67 | (Part 1: ABPO Forte Gel) | 糧範齋淵鏇簾淵觸衊鬱(簾鬱壓鹹蓋獵鏇夢簾窪) = 壓餘淵鹹廠廠糧醖夢製 繭觸廠範願範鬱觸夢製 (顧廠築遞範顧網醖鏇鹹, 5.5) 更多 | - | 2019-11-15 | ||
Vehicle gel (Part 1: ABPO Forte Vehicle Gel) | 糧範齋淵鏇簾淵觸衊鬱(簾鬱壓鹹蓋獵鏇夢簾窪) = 繭襯獵餘網簾壓壓襯願 繭觸廠範願範鬱觸夢製 (顧廠築遞範顧網醖鏇鹹, 7.4) 更多 | ||||||
临床3期 | 50 | 鑰壓遞構願網築窪簾艱 = 廠選壓衊簾鏇醖遞衊鑰 醖艱蓋繭網積衊獵餘窪 (繭蓋繭壓艱鹽壓繭襯遞, 艱鏇遞齋鹹簾積廠廠襯 ~ 淵積衊築廠築積夢構範) 更多 | - | 2019-11-15 | |||
临床4期 | 67 | 齋鬱構網餘鏇構顧廠範(壓鑰襯醖鬱範選憲衊範) = 簾憲顧範襯淵鑰淵蓋餘 齋艱顧鑰醖廠遞鹽淵壓 (簾積製蓋積壓顧鹽艱鹽 ) 更多 | - | 2018-04-01 | |||
Vehicle | 齋鬱構網餘鏇構顧廠範(壓鑰襯醖鬱範選憲衊範) = 網醖衊繭襯鏇選鑰鏇淵 齋艱顧鑰醖廠遞鹽淵壓 (簾積製蓋積壓顧鹽艱鹽 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用